Related Experiment Video
Updated: Mar 30, 2026

Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach
Published on: December 1, 2011
Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice
Claudia Palladino1, María Luisa Navarro Gómez, Pere Soler-Palacín
1aResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal bSección de Enfermedades Infecciosas, Servicio de Pediatría, Hospital General Universitario 'Gregorio Marañón', Madrid cUnitat de Patologia Infecciosa i Immunodeficiències de Pediatria, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona dServicio de Infecciosas Pediátricas, Hospital Universitario 'Doce de Octubre', Madrid eLaboratorio InmunoBiología Molecular, Hospital General Universitario 'Gregorio Marañón', Instituto de Investigación Sanitaria 'Gregrio Marañón' (IiSGM), Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid fUnidad de Estadística y Bioinformática. Institut de Recerca Vall d'Hebron, Barcelona gUnidad Medicina Interna Pediá[Combining Acute Accent]trica, Hospital Infantil Universitario 'Virgen del Rocío', Seville hUnidad Servicio de Pediatría, Hospital Universitario Germans Trias i Pujol Badalona iUnidad de Infectología e Inmunodeficiencias, Servicio de Pediatría, Hospital Regional Universitario 'Carlos Haya', Málaga jUnitat d'Infectologia, Servei de Pediatria; Hospital Sant Joan de Déu, Universitat de Barcelona kPediatric Service, Universitat Autónoma de Barcelona, Hospital del Mar, Barcelona lUnidad de Infectología Pediatrica, Hospital de Cruces, Bilbao mServicio de Enfermedades Infecciosas, Hospital Ramón y Cajal nUnit of Viral Infection and Immunity, National Center for Microbiology, Institute of Health Carlos III, Majadahonda. Madrid, Spain.
Abstract:
Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Drug Dosing: Infants and Children
Subviral Agents

